<DOC>
	<DOCNO>NCT00404833</DOCNO>
	<brief_summary>This prospective randomize open-label pilot study investigate effect mycophenolate mofetil treatment patient abnormal urine protein excretion due membranous nephropathy ( MN ) focal segmental glomerulosclerosis ( FSGS ) . The change urine protein excretion primary outcome study . The treatment regimen comprise prednisolone mycophenolate mofetil compare prednisolone chlorambucil MN , compare prednisolone FSGS . The study duration 12 month patient .</brief_summary>
	<brief_title>Mycophenolate Mofetil Membranous Nephropathy Focal Segmental</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>abnormal urine protein excretion biopsyproven idiopathic membranous nephropathy focal segmental glomerulosclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>idiopathic membranous nephropathy focal segmental glomerulosclerosis</keyword>
</DOC>